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Summary 
Metformin is the first line therapy of type 2 diabetics, but 
continued reduction of their life expectancy warrants further 
investigation into alternative treatment strategies. This study 
reports on the combinational use of metformin with aspalathin, 
a C-glucosyl dihydrochalcone with known glucose lowering and 
antioxidant properties, as an effective hypoglycemic therapy in 
a type 2 diabetic (db/db) mouse model. When tested as 
a monotherapy, a low dose of aspalathin (13 mg/kg) showed no 
effect, while a high dose (130 mg/kg) has already displayed 
a better potential than metformin in protecting against diabetes 
associated symptoms in db/db mice. Thus, it remains of interest 
to determine whether this dihydrochalcone can improve the 
efficacy of metformin. The results showed that this combination 
therapy was more effective than the use of metformin as 
a monotherapy in ameliorating diabetes associated symptoms, 
including abnormal raised fasting plasma glucose levels, impaired 
glucose tolerance, as well as excessively increased body weights 
and fat content. The treated mice also had reduced food and 
water consumption when compared to untreated controls, with 
a pronounced effect evident in the last week of treatment. 
Therefore, this study supports further investigations into the 
ameliorative effect of combination therapy of metformin and 
aspalathin against diabetes associated symptoms. 
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Metformin is a well-established first-line drug 
for the treatment of type 2 diabetes mellitus. In addition 
to lowering blood glucose levels and improving insulin 
sensitivity, mainly through enhancing skeletal muscle or 
adipose glucose uptake and suppressing hepatic glucose 
production, metformin presents some antiinflammatory 
and oxidative stress ameliorative properties that are 
important in combating diabetes associated symptoms 
(Hur and Lee 2015). However, due to the rapid rise in 
diabetes related deaths (International Diabetes Federation 
2017), it is hypothesized that the glucose-lowering 
efficacy of metformin might diminish over time. 
Furthermore, the efficacy of metformin can be influenced 
by genetic variation for some individuals, for example 
those that lack the organic cation transporter 1 (Oct1) 
gene, which is a major thiamine transporter of this 
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biguanide predominantly expressed in the liver (Shu et al. 
2007). This suggests that dual therapy approaches which 
improves the efficacy of metformin in individuals lacking 
Oct1 are likely to be beneficial. Indeed, increased 
exploration of combination drug therapy as an additional 
mechanism to improve metformin efficacy has been 
evident (Frendo-Cumbo et al. 2016, Wu et al. 2016). 
Of interest is the use of metformin in 
combination with aspalathin, a C-glucosyl 
dihydrochalcone abundantly found in rooibos 
(Aspalathus linearis) with known metabolic benefits. 
Literature on the beneficial effects of aspalathin or its 
enriched green rooibos extract has recently been reviewed 
by our group (Johnson et al. 2018). In addition to its 
enhanced capacity to reduce elevated fasting blood 
glucose concentrations in obese and diabetic rodent 
models, the strong antioxidant and antiinflammatory 
properties of aspalathin in preventing diabetes associated 
symptoms are discussed. Furthermore, we have recently 
demonstrated interesting data showing that an add-on 
effect of metformin and aspalathin is more effective than 
the use of each compound alone in preventing shifts in 
substrate preference and apoptosis in cultured 
cardiomyocytes exposed high glucose concentrations 
(Johnson et al. 2016). In a type 2 diabetic (db/db) mice, 
an aspalathin dose of 130 mg/kg performs better than 
metformin in ameliorating diabetes associated cardiac 
injury (Dludla et al. 2017, Johnson et al. 2017). 
Therefore, it remains of interest to further assess the 
combinational use of this biguanide and aspalathin in the 
modulation of glucose homeostasis and associated 
complications in a db/db mouse model. 
All animal experiments were approved and 
performed according to the South African Medical 
Research Council (SAMRC) Ethics Committee for 
Research on Animals (ECRA no. 07/13), and the 
Stellenbosch University Ethics Committee  
(SU-ACUM13-00021). Male C57BLKS/J homozygous 
(db/db) mice and their heterozygous leptin-receptor-
deficient nondiabetic lean littermate controls (db/+) were 
obtained from Jackson’s Laboratories (Sacramento, CA, 
USA) and housed, individually in a cage, at the Primate 
Unit and Delft Animal Centre (PUDAC) of the SAMRC 
in a controlled environment with a twelve-hour light/dark 
cycle (lights switched on at 6:00 AM and switched off at 
6:00 PM), in a temperature range of 23-25 °C (relative 
humidity: ∼50 %). Mice had unlimited access to water 
and standard mouse chow (Afresh Vention, Cape Town, 
South Africa). 
Nine-week old db/db mice together with their 
db/+ controls (n=6/per group) were randomly divided 
into 5 groups. Diabetic mice were treated daily for six 
weeks through oral gavage with metformin (150 mg/kg) 
monotherapy or a combination of metformin (150 mg/kg) 
with a low dose (13 mg/kg/day) or high dose 
(130 mg/kg/day) aspalathin. Untreated nondiabetic (db/+) 
and untreated diabetic (db/db) mice served as controls. 
Aspalathin (batch: SZI-356-54) was synthesized by High 
Force Research (Durham, UK) as per previously 
published protocol (Han et al. 2014) while metformin 
(99 % purity) was bought from Sigma-Aldrich (St. Louis, 
MO, USA). Treatment compounds were dissolved in 
distilled water before orally administration daily at the 
same time (08:00-09:00 AM), while untreated animals 
were given water in place of treatment. Metformin and 
aspalathin doses were based on previously published 
studies (Dludla et al. 2017, Johnson et al. 2017). 
Body weights, food and water intake as well as 
fasting plasma glucose concentrations were determined at 
baseline and every week for six weeks. The cages were 
changed regularly to avoid dirtiness that may interfere 
with food measurements. Porcelain containers with stand 
were used to provide food and the design of the 
containers prevented them from being tipped over, hence 
avoiding the spillage of food. The intake for each mouse 
could be monitored since they were caged individually. 
Fasting plasma glucose concentrations were determined 
on a weekly basis on 4 h fasted mice by tail pricks using  
a OneTouch Select handheld glucometer (LifeScan, 
Milpitas, CA, USA). The oral glucose tolerance test was 
done after the six-week treatment period. Briefly, after  
a 16-hour fast, mice were given treatments an hour earlier 
and allowed to settle for an additional hour before  
a 2 g/kg glucose was orally administered through gastric 
gavage before plasma glucose concentrations were 
determined by tail prick at time intervals of 0, 30, 60, and 
120 min. Homeostatic model assessment-insulin 
resistance (HOMA-IR) was calculated using fasting 
plasma glucose and fasting plasma insulin values, as per 
previously described method (Matthews et al. 1985). 
Fasting plasma insulin was determined using the 
radioimmunoassay kit (Linco Research, Inc., St. Charles, 
MO, USA), as per manufacturer's instructions. 
After the six-week treatment period, mice were 
fasted for 4 h and body weight measurements 
documented before being anesthetized with halothane 
(Safeline Pharmaceuticals; Johannesburg, South Africa). 
Mice received the anesthetic until no reaction could be 
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recorded by pedal reflex before fats (gonadal and 
intraperitoneal) were removed and weighed. 
Results were expressed as the mean ± SEM. 
Each treatment group contained six mice. Statistical 
analysis was performed using GraphPad Prism software 
version 5.0 (GraphPad Software, Inc., La Jolla, CA, 
USA). Comparisons between groups were performed 
using one-way multivariate ANOVA followed by  
a Tukey post hoc, while two-way ANOVA was used for 
multiple comparisons. A p˂0.05 was deemed as 
statistically significant. 
Leptin receptor deficient (db/db) mice provide 
an essential model to study type 2 diabetes associated 
symptoms. These mice spontaneously become obese and 
hyperglycemic, and in the process display similar features 
to type 2 diabetic individuals, for example they develop 
insulin resistance, which may initiate as early as the sixth 
week of age (King 2012). This explains the use of this 
model to assess the therapeutic potential of various drug 
compounds, including aspalathin for their antidiabetic 
activity (Kawano et al. 2009, King 2012, Johnson et al. 
2017). 
The current study showed that untreated nine-
week-old db/db mice, compared to nondiabetic controls, 
presented altered glucose homeostasis evident from 
irregularly elevated fasting plasma glucose 
concentrations, impaired oral glucose tolerance, as well 
as raised HOMA-IR, an accomplished measure of insulin 
resistance (Fig. 1A-D). Some of the additional anomalies 
displayed by untreated diabetic mice were significantly 
increased body weight, occurring concurrent to 
dysregulated food and water intake (Table 1; Fig. 2A, C, 
and D). This was consistent with an elevated fat to body 
weight ratio in untreated diabetic mice compared to 
untreated nondiabetic controls (Fig. 2B). However, the 
combination therapy presented a better effect than the use 
of metformin as a monotherapy in ameliorating diabetes 
associated symptoms assessed in our model (Table 1; 
Figs 1 and 2). However, from our results, inconsistencies 
were observed where treatment did not show a uniform 
effect for some parameters measured weekly, especially 
the fasting plasma glucose concentrations (Figs 1 and 2). 
Although several factors could explain this consequence, 
the small sample size of animals used per each group 
might be responsible, affecting the confidence intervals 
and p-values as previously reported (Du Prel et al. 2009, 
Dludla et al. 2017). Other factors could relate to the 
severity of this diabetic model, presenting with high 
levels of hyperglycemia which could not be properly 
monitored with the use of One Touch Select glucometers, 
suggesting that other sensitive methods like ELISA kits 
should be considered for future studies. Nonetheless, 
although the effect was moderate and hardly separable 
between both doses assessed, a low dose (13 mg/kg/day) 
of aspalathin showed a better effect than its high dose in 
reducing raised blood glucose concentrations and 
improving glucose tolerance, while the high dose 
(130 mg/kg/day) showed a greater effect in reducing fat 
content and increased body weights than the low dose. 
Interestingly, the effect of both doses was more 
pronounced in the last week of treatment (week six), 
suggesting that long-term treatment with combination 
therapy might be more effective than short term 
treatment. However, this hypothesis needs further 
assessment since it already known that aspalathin 
demonstrates low bioavailability when assessed using  
an in vitro intestinal epithelial monolayer (Caco-2) 
transport model (Bowles et al. 2017). 
This is the first study to report on the beneficial 
effect of combining metformin and aspalathin in 
ameliorating diabetic associated symptoms in a db/db 
mouse model. Furthermore, the results presented here 
support available data showing the superior effect of 
metformin when combined with natural products such as 
resveratrol, a phytoalexin stilbenoid, or salvianolic 
acid A, a polyphenol derivative isolated from the roots of 
Salvia miltiorrhiza, in combating diabetic symptoms in 
high fat diet fed or streptozotocin-induced diabetic mice 
(Frendo-Cumbo et al. 2016, Wu et al. 2016). The 
beneficial effect of combination therapy from these 
studies is partially modulated through regulation of 
phosphatidylinositol-4,5-bisphosphate 3-kinase/protein 
kinase B (PI3K/AKT), AMP-activated protein kinase 
(AMPK), as well as nuclear factor (erythroid-derived 2)-
like 2 (NRF2), the well-investigated signaling 
mechanisms involved in insulin signaling and prevention 
of hyperglycemia-induced complications such as 
inflammation and oxidative stress. Interestingly, similar 
mechanisms have also been identified by studies 
assessing the antidiabetic potential of aspalathin or in 
combination with metformin, as recently reviewed by our 
group (Johnson et al. 2018). Such combination therapy 
has the potential to provide value to effective 
management of diabetes mellitus. Aspects that still need 
investigation are molecular mechanisms associated with 
the beneficial effect of combination therapy of metformin 
and aspalathin, the pharmacokinetics profile, and the 
long-term effect of this treatment. 
 





Fig. 1. The combination effect of metformin and aspalathin on fasting plasma glucose levels (A), homeostasis model assessment: 
insulin resistance (HOMA-IR; (B), impaired glucose tolerance (C), and area under the curve (D) in db/db mice. Each value represents 
the mean ± SEM of six mice. Comparisons between groups were performed using one-way multivariate ANOVA followed by a Tukey 
post hoc, while two-way ANOVA was used for multiple comparisons. A p˂0.05 was deemed as statistically significant. Although not 
represented on graphs A and B, all diabetic animals (db/db) showed significant difference (p˂0.001) when compared to nondiabetic 
control (db/+). a p<0.05, aaa p<0.001 versus db/+; b p<0.05 versus db/db; d p<0.05 versus diabetic mice treated with metformin and  
a low dose aspalathin (db/db + MET + ASP LD); and e p<0.05 versus diabetic mice treated with metformin and a high dose aspalathin 




Table 1. Body weights, cumulative food and water intakes, and insulin concentrations of rats treated for 6 weeks with metformin or  
a combination of metformin and aspalathin. 
 
 
db/+ db/db db/db + MET db/db + MET + ASP LD db/db + MET+ ASP HD 
BW (g) 27 ± 1 35 ± 2aa 36 ± 2aa 37 ± 2aa 36 ± 2aa 
CFI (g) 148 ± 7 279 ± 10aaa 260 ± 5aaa, b 247 ± 5aaa, bb 265 ± 7aaa, bb 
CWI (ml) 494 ± 7 1,075 ± 47aaa 1,015 ± 32aaa 951 ± 36aaa, bb 916 ± 33aaa, bbb, c 
INS (ng/ml) 0.4 ± 0.1 1.9 ± 1 1.1 ± 0.2 0.7 ± 0.1b 0.6 ± 0.3b 
 
Results are represented as the Mean ± SEM. aaa p<0.001, aa p<0.01 vs untreated nondiabetic control (db/+); bbb p<0.001, bb p<0.01, 
b p<0.05 vs. untreated diabetic control (db/db); and c p<0.05 vs. diabetic group treated with metformin only (db/db + MET). 
Abbreviations: ASP LD, aspalathin low dose; ASP HD, aspalathin high dose; BW, body weight; CFI, cumulative food intake; CWI, 
cumulative water intake; INS, insulin; MET, metformin. 




Fig. 2. The combination effect of metformin and aspalathin on body weights (A), fat weight to body weight (B), cumulative food intake 
(C), and cumulative water intake (D) in db/db mice. Each value represents the mean ± SEM of six mice. Although not represented on 
the graph A, C and D, all diabetic animals (db/db) showed significant difference (p˂0.001) when compared to nondiabetic control 
(db/+). aaa p<0.001 versus db/+; b p<0.05, bb p<0.001 versus db/db; c p<0.05, cc p˂0.01 versus diabetic mice treated with metformin 
only (db/db + MET); d p<0.05, dd p<0.01, ddd p<0.001 versus diabetic mice treated with metformin and a low dose aspalathin (db/db + 
MET + ASP LD); e p<0.05, ee p<0.01, eee p<0.001 versus diabetic mice treated with metformin and a high dose aspalathin (db/db + MET 
+ ASP LD). 
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